A case of catatonia and neuroleptic malignant syndrome probably associated with antipsychotic in Korea

Psychiatry Investigation

Volumn 8, Issue 2, 2011, Pages 174-177

  Choi, Ho Dong ^a   Kim, Kyoung Keun ^a   Koo, Bon Hoon ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Atypical antipsychotics; Catatonia; Neuroleptic malignant syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; CREATINE KINASE; IRON; OLANZAPINE; RISPERIDONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSISTED VENTILATION; AUDITORY HALLUCINATION; CASE REPORT; CATATONIA; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; CREATINE KINASE BLOOD LEVEL; CRYING; DELUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; DYSTONIA; ELECTROENCEPHALOGRAPHY; ENDOTRACHEAL TUBE; FEMALE; FEVER; FRONTAL LOBE; HUMAN; HYPERSALIVATION; INTENSIVE CARE UNIT; IRON BLOOD LEVEL; LARYNX SPASM; LEUKOCYTE COUNT; NASOGASTRIC TUBE; NEUROIMAGING; NEUROLEPTIC MALIGNANT SYNDROME; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SATURATION; RESTLESSNESS; RIGIDITY; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLOW BRAIN WAVE; STIMULUS RESPONSE; SUPRAVENTRICULAR TACHYCARDIA; THORAX RADIOGRAPHY; VERBALIZATION;

EID: 79960966877     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2011.8.2.174     Document Type: Article

References (36)

1. Fink M. Treating neuroleptic malignant syndrome as catatonia. J Clin Psychopharmacol 2001;21:121-122.
2. Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009;10:70-73.
3. Peralta V, Cuesta MJ, Serrano JF, Mata I. The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder. Compr Psychiatry 1997;38:61-67.
4. Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci 2002;25:555-577.
5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
6. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-1116.
7. Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the pathogenesis of the neuroleptic malignant syndrome. Psychiatr Ann 2000;30:363-374.
8. White DA. Catatonia and the neuroleptic malignant syndrome--a single entity? Br J Psychiatry 1992;161:558-560.
9. White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991;158:419-421.
10. Raja M, Altavista MC, Cavallari S, Lubich L. Neuroleptic malignant syndrome and catatonia. A report of three cases. Eur Arch Psychiatry Clin Neurosci 1994;243:299-303.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC: American Psychiatric Press; 2000.
12. Dhossche DM, Carroll BT, Carroll TD. Is there a Common Neuronal Basis for Autism and Catatonia? In: Dhossche D, Wing L, Ohta M, Neumarker K, Editors. Catatonia in Autism Spectrum Disorders. St. Louis, MO: Elsevier/Academic Press, Inc; 2006.
13. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992;31:1161-1164.
14. Tsai JH, Yang P, Yen JY, Chen CC, Yang MJ. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy 2005;25:1156-1159.
15. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004;19:351-353.
16. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004;26:1105-1108.
17. Zalsman G, Lewis R, Konas S, Loebstein O, Goldberg P, Burguillo F, et al. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 2004; 16:179-182.
18. Dew RE, Rosenquist PB, McCall WV. Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. Int J Adolesc Med Health 2005;17:187-188.
19. Kobayashi A, Kawanishi C, Matsumura T, Kato D, Furukawa R, Kishida I, et al. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1170-1172.
20. Norgard NB, Stark JE. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 2006;26:1180-1182.
21. Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990;2:251-253.
22. Lee JW. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry 2007;19:9-16.
23. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996;39:1-4.
24. Carroll BT, Taylor RE. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 1997;17: 235-238.
25. Carroll BT, Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995;38:776-777.
26. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995;29:233-244.
27. Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psy chol Med 1996;26:547-553.
28. Northoff G, Pfennig A, Krug M, Danos P, Leschinger A, Schwarz A, et al. Delayed onset of late movement-related cortical potentials and abnormal response to lorazepam in catatonia. Schizophr Res 2000;44:193-211.
29. Lew TY, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983;18:1441-1446.
30. Kontaxakis VP, Christodoulou GN, Markidis MP, Havaki-Kontaxaki BJ. Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand 1988;78:396-398.
31. Miyaoka H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K. Diazepam- responsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry 1997;154:882.
32. Koch M, Chandragiri S, Rizvi S, Petrides G, Francis A. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry 2000;41:73-75.
33. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-1020.
34. Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999; 2:129-144.
35. Carroll BT, Lee JW. Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry 2004;65:1722-1723.
36. Malur C, Pasol E, Francis A. ECT for prolonged catatonia. J ECT 2001; 17:55-59.